Steroid hormones in endometrial and breast cancer

European Journal of Gynaecological Oncology

Volumn 18, Issue 5, 1997, Pages 371-378

  Gadducci, A ^a   Genazzani, A R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Breast cancer; Endometrial cancer; Growth factor; Hormonal replacement therapy; Oral contraceptive; Steroid hormone

Indexed keywords

GROWTH FACTOR; STEROID HORMONE;

BREAST CANCER; CANCER GROWTH; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; REVIEW;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; ENDOMETRIAL NEOPLASMS; FEMALE; GROWTH SUBSTANCES; HORMONES; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASMS, HORMONE-DEPENDENT; STEROIDS;

EID: 0030778904     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Kumar V., Green S., Stack G., Berry M., Jin J. R., Chambon P.: "Functional domains of the human estrogen receptor". Cell., 1987, 51, 941
2. Law M. L., Kao F. T., Wei Q., Hartz J. A., Greene G. L., Zarucki-Schulz T. et al.: "The progesterone receptor maps to human chromosome band 11q13, the site of mammary oncogene int-2". Proc. Natl. Acad. Sci USA, 1987, 84, 2877.
3. Murphy L. J., Murphy L. C., Friesen H. G. "Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus". Endocrinology, 1988, 120, 1806.
4. Wcisz A., Bresciani F.: "Estrogen induces expression of c-fos and c-myc protooncogenes in rat uterus". Molec Endocrin., 1980, 2, 816.
5. Chiappetta C., Kirkland J. L., Loose-Mitchell D. S., Murthy L., Stancel G. M.: "Estrogen regulates expression of the jun family of proto-oncogenes in the uterus". J. Steroid. Biochem. Molec. Biol., 1992, 41, 113.
6. Brigstock D. R., "Growth factors in the uterus: steroidal regulation and biological responses". Bailliere's Clin. Endocr. Metab., 1991, 5, 791.
7. Gambrell R. D. Jr.: "Pathophysiology and epidemiology of endometrial cancer". In: "Treatment of the postmenopausal woman: basic and clinical aspects". (Lobo R. A. Eds.), Raven Press, New York, 1994, 355.
8. Murphy L. J.: "Growth factors and steroid hormone action in endometrial cancer". J. Steroid. Biochem. Molec. Biol., 1994, 48, 419.
9. Tseng L., Gurpide E.: "Effects of progestins on estradiol receptor levels in human endometrium". J. Clin. Endocr. Metab., 1975, 41, 402.
10. Tseng L., Gurpide E.: "Induction of human endometrial estradiol dehydrogenase by progestins". Endocrinology, 1975, 97, 825.
11. Tseng L., Lui H. C.: "Stimulation of arylsulfotransferase activity by progestins in human endometrium in vitro". J. Clin. Endocr. Metab., 1981, 53, 418.
12. Murphy L. J., Gong Y., Murphy L. C., Bhavnani B.: "Growth factors in normal and malignant uterine tissue". Ann. N. Y. Acad. Sci., 1991, 622, 383.
13. Reynholds R K., Talavera F., Roberts J. A., Hopkins M. P., Menon K. M. J.: "Regulation of epidermal growth factor and insuline-like growth factor I receptors by estradiol and progesterone in normal and neoplastic endometrial cell cultures". Gynecol. Oncol., 1990, 38, 396.
14. Gong Y., Ballejo G., Murphy L. C., Murphy L. J.: "Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells". Cancer Res., 1992, 52, 1704.
15. Damahanov I., Mildner B., Knowles B. B.: "Immunohistochemical localization of epidermal growth factor receptor in normal human tissues". Lab. Invest., 1986, 55, 588.
16. Taketani Y., Mizuno M.: "Cyclic changes in epidermal growth factor receptor in human endometrium during menstrual cycle". Endocrinol. Jpn., 1988, 35, 19.
17. Mukku V. R., Stancel G. M.: "Regulation of epidermal growth factor receptor by estrogen". J. Biol. Chem., 1985, 260, 9820.
18. Taketani Y., Mizuno M.: "Evidence for direct regulation of epidermal growth factor receptors by steroid hormones in human endometrial cells". Hum. Reprod., 1991, 6, 1365.
19. Watson H., Franks S., Bonney R. C.: "The epidermal growth factor receptor in the human endometrial adenocarcinoma cell line HEC-1-B". J. Steroid. Biochem. Molec. Biol., 1994, 51, 41.
20. Scambia G., Benedetti Panici P., Ferrandina G., Battaglia F., Distefano M., D'Andrea G. et al., "Significance of epidermal growth factor receptor expression in primary human endometrial cancer". Int. J. Cancer, 1994, 56, 26.
21. Roberts A. B., Sporn M. B.: "The trasnforming growth factor-B". In: "Peptide growth factors and their receptors". (Sporn M. B., Roberts A. B., Eds.), Springer-Verlag, Hidelberg, Germany, 1990, 419.
22. Morales T. I., Roberts A. B.: "Transforming growth factor-B regulates the metabolism of proteoglycans in bovine cartilage organ cultures". J. Biol. Chem., 1988, 263, 12828.
23. Laiho M., Saksela O., Keski-Oja J : "Transforming growth factor-B induction of type-I plasminogen activator inhibitor". J. Biol. Chem., 1987, 262, 17467.
24. Gold L. I., Saxena B., Mittal K. R., Marmor M., Goswami S., Nactigal L. et al.: "Increased expression of transforming growth factor-B isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action". Cancer Res., 1994, 54, 2347.
25. Lund P. K., Moats-Staats B. M., Hynes M. A., Simmons J. D., Jansen M., D'Ercole A. J., Van Wyk J. J.: "Somatomedin/insulin-like growth factor-I and insulin-like growth factor-II mRNAs in rat fetal and adult tissues". J. Biol. Chem., 1986, 261, 14539.
26. Bohem K. D., Daimon M., Gorodeski I. G , Sheean L. A., Utian W. H., Ilan J.: "Expression of insulin-like and platelet-derived growth factor genes in human uterine tissues". Mol. Reprod. Dev., 1990, 27, 93.
27. Rutanen E. M., Pekonen F., Makinen T.: "Soluble 34K binding protein inhibits the binding of insulin like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action". J. Clin. Endocrin. Metab., 1988, 66, 173.
28. Talavera F., Reynolds R. K., Roberts J. A., Menon K. M. J.: "Insulin-like growth factor receptors in normal and neoplastic human endometrium". Cancer Res., 1990, 50, 3019.
29. Pekonen K., Nyman T., Rutanen E. M.: "Human endometrial adenocarcinoma cell lines HEC 1B and KLE secrete insulin-like growth factor-binding protein-1 and contain IGF-1 receptors". Mol. Cell. Endocrinol., 1991, 75, 81.
30. Shimasaki S., Ling N.: "Identification and molecular characterization of insulin-like growth factor-binding protein (IGFBP-1, -2, -3, -4, -5 and -6)". Pog. Growth Factor Res., 1991, 3, 243.
31. Rutanen E. M., Nyman T., Lehtovirta P., Ammala M., Pekonen F.: "Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors". Int. J. Cancer, 1994, 59, 307.
32. Giudice L. C., Dsupin B. A., Irwin J. C.: "Steroid and peptide regulation of insulin-like growth factor-binding proteins secreted by human endometrial stromal cells is dependent on stromal differentiation". J. Clin. Endocrin. Metab., 1992, 75, 1235.
33. Pekonen F., Nyman T., Lahteenmaki P., Haukkamaa M., Rutanen E. M.: "Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium". J. Clin. Endocrin. Metab., 1992, 75, 660.
34. Rutanen E. M., Stenman S., Blum W., Karkkainen T., Lehtovirta P., Stenman U. H.: "Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls". J. Clin. Endocrin. Metab., 1993, 77, 199.
35. Pearl M. L., Talavera F., Gretz H. F. III. Roberts J. A., Menon K. M. J.: "Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC-1-A and KLE". Gynecol. Oncol., 1993, 49, 325
36. Anzai Y., Gong Y., Holinka C. F., Murphy L. J., Murphy L. C., Kuramoto H., Gurpide E.: "Effects of transforming growth factors and regulation of their mRNA levels in two human endometrial adenocarcinoma cell lines" J. Steroid. Biochem. Molec. Biol., 1992, 42, 449.
37. Presta M.: "Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implication for neovascularization of normal and neoplastic endometrium". J. Cell. Physiol., 1988, 137, 593.
38. Rusnati M., Casarotti G., Pecorelli S., Ragnotti G., Presta M.: "Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium". Growth Factors, 1990, 3, 299.
39. Rusnati M., Casarotti G., Pecorelli S., Ragnotti G., Presta M.: "Estro-progestinic replacement therapy modulates the levels of basic fibroblast growth factor (bFGF) in postmenopausal endometrium". Gynecol. Oncol., 1993, 48, 88.
40. Tabibzadeh S.: "Human endometrium: an active site of cytokine production and action". Eudocr. Rev., 1991, 12, 272.
41. Hulka B. S., Chambless L. E., Kaufman D. G., Fowler W. C. Jr., Greenberg B. G.: "Protection against endometrial carcinoma by combination product oral contraceptives". JAMA, 1982, 247, 475.
42. Centers for Disease Control. "Oral contraceptive use and the risk of endometrial cancer". JAMA, 1983, 249, 1602.
43. Dahmoush L., Pike M. C., Press M. F.: "Hormones and breast-cell proliferation". In. "Treatment of the postmenopausal woman: basic and clinical aspects". (Lobo R. A. Eds.), Raven Press Ltd, New York, 1994, 325.
44. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D.: "Hormone replacement therapy and endometrial cancer risk: a meta-analysis" Obstet. Gynecol., 1995, 85, 304.
45. Whitehead M. I., Fraser D.: "Controversies concerning the safety of estrogen replacement therapy". Am. J. Obstet. Gynecol., 1987, 156, 1313.
46. American College of Obstetrics and Gynecology. "Hormone replacement theapy". ACOG Tech. Bull., 1992, 166, 1.
47. Hammond C., Jelovsek F., Lee K., Creasman W., Parker R : "Effects of long-term estrogen replacement therapy. II Neoplasia". Am. J. Obstet. Gynecol., 1979, 133, 537.
48. Nachtigall L. E., Nachtigall R. H., Nachtigall R. D., Beckman E.: "Estrogen replacement therapy. II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems". Obstet. Gynecol., 1979, 54, 74.
49. Gambrell R. Jr., Massey F., Castaneda T. et al.: "Use of progestogen challenge test to reduce the risk of endometrial cancer". Obstet. Gynecol., 1980, 55, 732.
50. Persson I., Adami H. O., Bergkvist L., Lindgren A., Pettersson B., Hoover R., Schairer C.: "Risk of endometrial cancer after treatment with oestrogens alone or in conjuction with progestogens: results of a prospective study". Br. Med. J., 1989, 298, 147.
51. Voigt L., Weiss N., Chu J., Daling J., McKnight B., vanBelle G.: "Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer". Lancet, 1991, 338, 274.
52. Jick S., Walker A., Jick H.: "Estrogen, progesterone, and endometrial cancer". Epidemiology, 1993, 4, 20.
53. Brinton L., Hoover R.: "Estrogen replacement therapy and endometrial cancer risk: unresolved issues". Obstet, Gynecol., 1993, 81, 265.
54. McGonigle K. F., Karlan B. Y., Barbuto D. A., Leuchter R. S., Lagasse L. D., Judd H. L.: "Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy". Gynecol. Oncol., 1994, 55, 126.
55. Creasman W. T., Henderson D., Hinshaw W., Clarke Pearson D. L.: "Estrogen-replacement therapy in the patients treated for endometrial cancer". Obstet. Gynecol., 1986, 67, 326.
56. Lee R. B., Burke T. W., Park R. C.: "Estrogen replacement therapy following treatment for stage I endometrial carcinoma". Gynecol. Oncol., 1990, 36, 189.
57. Yasuda M., Kurabayashi T., Yamamoto Y., Fujimaki T., Oda K.,Tanaka K.: "Effect of hormone replacement therapy on bone and lipid metabolism in womn oophorectomized for the treatment of gynecologic malignancies". Int. J. Gynecol. Obstet., 1994, 47, 151.
58. Howell A.: "Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer". Proc. Royal Society of Edinburgh, 1989, 95B, 49.
59. Jacquemier J. D., Hassoun J., Torrente M., Martin P. M.: "Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages-immunohistochemical study of 107 cases". Breast Cancer Res. Treat., 1990, 15, 109.
60. Ricketts D., Turnbull L., Ryall G. et al.: "Estrogen and progesterone receptors in the normal female breast". Cancer Res, 1991, 51, 1817.
61. Williams G., Anderson E., Howell A., Watson R., Coyne J., Robberts S. A., Potten C. S.: "Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of the epithelial cells in the normal human breast". Int. J. Cancer. 1991, 48, 206.
62. Battersby S., Robertson B. J., Anderson T. J., King R. J. B., McPherson K.: "Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast". Br. J. Cancer. 1992, 65, 601.
63. Meyer J. S.: "Cell proliferation in normal human breast ducts, fibroadenomas, and other duct hyperplasias, measured by nuclear labeling with tritiated thymidine". Hum. Pathol., 1977, 8, 67.
64. Anderson T. J., Battersby S., King R. J. B., McPherson K., Going J. J.: "Oral contraceptive use influences resting breast proliferation". Hum. Pathol., 1989, 20, 1139.
65. McManus M. J., Welsch C. W.: "The effects of estrogens, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice". Cancer, 1984, 54, 1920.
66. Longman S. M., Buehring G. C.: "Oral contraceptives and breast cancer. In vitro effects of contraceptive steroids on human mammary cell growth". Cancer. 1987, 59, 281.
67. Mauvasis-Jarvis P., Kuttenn F., Gompel A.: "Anti-estrogen action of progesterone in breast tissue". Breast Cancer Res. Treat., 1986, 8, 179.
68. Allegra J. C., Kiefer S. M.: "Mechanisms of action of progestational agents". Semin. Oncol., 1985, 2, 3.
69. Clarke CI., Sutherland R. L.: "Progestin regulation of cellular proliferation". Endocr. Rev., 1990, 11, 266.
70. Dickson R. B., Huff K. K., Spencer E. M., Lippman M. E.: "Induction of epidermal growth factor-related polypeptides by 17-beta oestradiol in MCF-7 human breast cancer cell lines". Endocrinol., 1986, 118, 138.
71. Bates S. E., Davidson N. E., Valverius E., Freter C., Dickson R. B., Tam J. D. et al.: "Expression of trasforming growth factor alpha and its messengers ribomekic acid in human breast cancer: its regulation by estrogen and its possible functional significance". Mol. Endocrinol., 1988, 2, 543.
72. Wang J. L., Hsu Y. M.: "Negative regulators of cell growth". Trends in Biochemical Science, 1986, 11, 24.
73. Knabbe C., Lippman M. W., Wakefield L., Flanders K., Kasid A , Derynck R., Dickson R. B.: "Evidence that TGF-B is hormonally regulated negative growth factor in human breast cancer". Cell., 1987, 48, 417.
74. Lippman M. E., Dickson R. B.: "Growth control of normal and malignant breast epithelium". Proc. Royal Society of Edinburgh, 1989, 95B, 89.
75. Rohlik Q. T., Adams D. M., Kull F. C., Jacobs S.: "An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture". Biochem. Biophys. Res. Comm., 1988, 149, 276.
76. Chen J. C., Shao Z. M., Sheikh M. S., Hussain A., LeRoith D., Roberts C. T. Jr., Fontana J. A.: "Insulin-like growth factor binding protein enhancement of insulin-like growth factor-1, IGF-I, mediated DNAsynthesis and IGF-I binding in a human breast carcinoma cell line". J. Cell. Physiol., 1994, 158, 69.
77. Figueroa J. A., Jackson J G., McGuire W. L., Krywicki R. F., Yee D.: "Expression of insulin-like growth factor binding protein in human breast cancer correlates with estrogen receptor status". J. Cell. Biochem., 1993, 52, 196.
78. DiSaia P. J.: "Hormone-replacement therapy in patients with breast cancer". Cancer, 1993, 71 (Suppl.), 1490.
79. Danforth D. N.: "How subsequent pregnancy affects outcome in women with a prior breast cancer" Oncology, 1991, 5, 23.
80. Schlesselman J. J.: "Cancer of the breast and reproductive tract". Contraception, 1989, 40, 1.
81. Romieu I., Willette W. C., Colditz G. A., Stampfer M. J., Rosner B., Hennekens C. H. et al.: "Prospective study of oral contraceptive use and risk of breast cancer in women". J. Natl. Cancer Inst., 1989, 81, 1313.
82. Vessey M. P., McPherson K., Villard-Mackintosh L., Yeates D.: "Oral contraceptives and breast cancer: latest findings in a large cohort study". Br. J. Cancer, 1989, 59, 613.
83. Wingo P. A., Lee N. C., Ory H. W., Beral V., Peterson H. B., Rhodes P.: "Age-specific differences in the relationship between oral contraceptive use and breast cancer". Cancer. 1993, 71 (Suppl.), 1506.
84. The Centers for Disease Control and National Institute of Child Health and Human Development Cancer and Steroid Hormone Study. "Oral contraceptive use and the risk of breast cancer". N. Engl. J. Med., 1986, 315, 405.
85. Rosner D., Lane W. W.: "Oral contraceptive use has no adverse effect on prognosis of breast cancer". Cancer, 1986, 57, 591.
86. ACOG Committee Opinion: Committe on Gynecologic Practice. "Estrogen replacement therapy in women with previously treated breast cancer". Int. J. Gynecol. Obstet., 1994, 45, 184.
87. Dupont W. D., Page D. L.: "Menopausal estrogen replacement therapy and breast cancer". Arch. Intern. Med., 1991, 151, 67.
88. Grady D., Ernster V.: "Does postmenopausal hormone therapy cause breast cancer?". Am. J. Epidemiol., 1991, 134, 1396.
89. Sillero-Arenas M., Delgado-Rodriguez M., Rodrigues-Canteras R , Bueno-Cavanillas A , Galvez-Vargas R.: "Menopausal hormone replacement therapy and breast cancer: a meta-analysis". Obstet. Gynecol., 1992, 79, 286.
90. Steinberg K. K., Thacker S. B., Smith S. J., Stroup D. F., Zack M. M., Flanders W. D.: "A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer". JAMA, 1991, 265, 1985.
91. Spratt J. S., Donegan W. L., Greenberg R. A.: "Epidemiology and etiology". In: "Cancer of the breast". (Donegan W. L., Spratt J. S. Eds), 3rd ed., Philadelphia, W. B. Saunders, 1988, 56
92. Wile A. G., Opfell R. W., Margileth D. A.: "Hormone replacement therapy in previously treated breast cancer patients". Ant. J. Sarg., 1993, 165, 372.
93. Bergkwist L., Adami H. O., Persson I., Bergstrom R., Krusemo U. B.: "Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progesterone replacement therapy". Am. J. Epidemiol., 1992, 130, 221.
94. Gambrell D. R.: "Proposal to decrease the risk and improve the prognosis in breast cancer". Am. J. Obstet. Gynecol., 1984, 150, 119.
95. Bonnier P., Romain S., Giacalone P. L., Laffargue F., Martin P. M., Piana L.: "Clinical and biological prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy". Obstet. Gynecol., 1995, 85, 11.
96. Cobleigh M. A., Berris R. F., Bush T., Davidson N. E., Robert N. J., Sparano J. A. et al.: "Estrogen replacement therapy in breast cancer survivors. A time for change". JAMA, 1994, 272, 540.
97. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormone, cytotoxic or immune therapy". Lancet, 1992, 339, 71.
98. Stoll B. A.: "Hormone replacement therapy in women treated for breast cancer". Eur. J. Cancer Clin. Oncol., 1989, 25, 1909.
99. Wren B. G.: "Hormone therapy following breast and uterine cancer". Bailliere's Clin. Endocrinol. Metabol., 1993, 7, 225.
100. Vassillopoulou-Sellin R., Theriault R. L.: "Randomized prospective trial of ERT in women with a history of breast cancer". J. Natl. Cancer Inst. Monogr., 1994, 16, 153.
101. O'Brien C. A., Liskamp R. M., Solomon D. H., Weinstein I. B.: "Inhibition of protein kinase C by tamoxifen". Cancer Res., 1985, 45, 2462.
102. Lam H.-Y P: "Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase". Biochem. Biophys. Res. Commun , 1984, 118, 27.
103. Berry J., Green B. J., Mathenson D. S.: "Modulation of natural killer cell activity by tamoxifen in stage I postmenopausal breast cancer patients". Eur. J. Cancer Clin. Oncol., 1987, 23, 517.
104. Manning D. L., Nicholson R. I., Eaton C L.: "Role of oestrogens and growth factors in the aetiology of breast cancer". In: "Recent Advances in Endocrinology and Metabolism". (Edwards C., Lincoln D., Eds.). Edinburgh: Churchill Livingstone. 1992, 133.
105. Powles T. J.: "Tamoxifen and oestrogens replacement therapy". Lancet, 1990, 336, 48.
106. Heuson J. C.: "Current overview of EORTC clinical trials with tamoxifen". Cancer Treat. Rep., 1976, 60, 1463.
107. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Coutere J. et al.: "A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors". N. Engl. J. Med., 1989, 320, 479.
108. American College of Physicians. "Guidelines for counseling postmenopausal women about preventive hormone therapy". Ann. Intern. Med., 1992, 117, 1038.
109. American College of Obstetricians and Gynecologists. "Hormone Replacement therapy". Washington; D. C.: American College of Obstetricians and Gynecologists, April 1992, 166.
110. Petru E., Lahousen M., Urdl W., Luschin G., Pickel H.: "Hormonsubstitution bei patientinnen nach primarbehandlung gynakologischer malignome". Wien Med. Wochenschr., 1993, 143, 539.
111. Gorsky R. D., Koplan J. P., Peterson H. B., Thacker S. I.: "Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis". Obstet. Gynecol., 1994, 83, 161.